CRSP

39.1000.44%
RY

Raju Yashaswi Prasad

Executive Officer

Dr. Raju Yashaswi Prasad, Ph.D., was Chief Financial Officer at CRISPR Therapeutics AG since March 14, 2023 until October 19, 2026. He will remain with CRISPR Therapeutics AG until November 30, 2026. He also serves as Chief Financial Officer at CRISPR Therapeutics, Inc. since March 14, 2023 and serves as Director at Averna Therapeutics Inc. He was an Advisory Board Member at Portal Innovations, LLC until August 2026. He served as Senior Research Analyst at William Blair & Company L.L.C., Research Division from August 2017 and also served as Analyst. He joined the firm in March 2014. He focused on Biotechnology & Therapeutics. He holds a Ph.D. in Engineering, Environmental Science & Genetic Toxicology from the University Of North Carolina At Chapel Hill, an M.S. in Exercise Physiology from the University of Delaware and a B.A. in Cellular Biology & Neuroscience from Rutgers, The State University of New Jersey.

Positions